SERPINF2

Across TCGA pan-cancer cohorts, SERPINF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SERPINF2 data layer compared with 24 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SERPINF2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SERPINF2 expression acts as an unfavorable survival marker.

BLCA, LUSC, and LIHC are the cancer types where SERPINF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.124	0.626	.002	30	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
LIHC	OS	Median	All	0.164	0.704	.025	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SERPINF2–BLCA (DFS)

Open the BLCA breakdown →